Skip to main content
News Icon

News categories: Publication

CRC for Brown and Beige Fat Organ Crosstalk, Signaling and Energetics

Prof. Dr. med. Alexander Pfeifer becomes speaker of the newly founded Collaborative Research Center for Brown and Beige Fat Organ Crosstalk, Signaling and Energetics

Worldwide, the number of overweight and obese patients is increasing, and consequently diabetes and cardiovascular disease. Obesity is also a risk factor for developing severe Covid19. In the Transregional Collaborative Research Centre (CRC) 333 "Brown and Beige Fat Organ Crosstalk, Signaling and Energetics ( BATenergy)", researchers from the University of Bonn and the University Hospital Bonn, the University Medical Center Hamburg-Eppendorf (UKE), the Technical University of Munich (TUM) and the Helmholtz Zentrum München are investigating different types of adipose tissue and their role in metabolic diseases. As speaker of the CRC, Prof. Dr. med. Alexander Pfeifer, member of ImmunoSensation2 and head of the institute of Pharmacology and Toxicology at the University Clinics Bonn, was appointed.

The CRC’s research focus lies on brown fat cells, which are specialized in converting energy into heat. This makes them fundamentally different from white fat cells, which store energy in the form of fat. But even in white adipose tissue there are isolated brown fat cells, called "beige" cells. The goal of the CRC is to characterize the function of brown adipose cells at all levels, to uncover new communication pathways within our body, and thus to develop new therapeutic approaches for metabolic diseases in the future.

Brown adipose tissue is activated by cold. The researchers want to identify the body's own messenger substances and find out how different organs regulate brown fat. "This will provide a new picture of mutual communication of adipose tissue with other metabolic organs," says Prof. Dr. Alexander Pfeifer.

In their projects, the teams use state-of-the-art molecular biology methods as well as cell culture systems of fat cells and investigate metabolism from mice to humans. In this way, they hope to uncover new molecular mechanisms and target structures for drugs. On the long term, this should lead to new therapeutic approaches for the treatment of metabolic disease.

The vice speakers Prof. Dr. Jörg Heeren from the Institute of Biochemistry and Molecular Cell Biology of the UKE and Prof. Dr. Henriette Uhlenhaut from the TUM School of Life Sciences emphasize that the CRC uniquely brings together expert teams from metabolism research at three German Universities of Excellence and the Helmholtz Zentrum in Munich.

The CRC is thematically embedded in the Transdisciplinary Research Areas "Life and Health" and "Sustainable Futures" of the University of Bonn. At the UKE, the CRC is thematically assigned to the interdisciplinary research area C3I (Center for Inflammation, Infection and Immunity).

Contact

Prof. Dr. med. Alexander Pfeifer

Institute of Pharmacology and Toxicology

University of Bonn

Phone: +49-228-287-51300/51302

Email: alexander.pfeifer@uni-bonn.de

Related news

News Icon

News categories: Publication

Diets need more sustainability

There has been a rapid increase in cardiovascular and metabolic conditions in sub-Saharan Africa. What is the link between sustainable diets that are nutritious, environmentally friendly, economically affordable, and socioculturally acceptable, and cardiometabolic conditions? An international research team led by Prof. Dr. Ina Danquah, Hertz Chair for Innovation for Planetary Health and Director at Center for Development Research (ZEF) at University of Bonn, investigated this question among Ghanaian adults who live in various locations.
View entry
Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

News categories: Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

News categories: Publication

A Ray of Hope in the Fight Against Cancer

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry

Back to the news overview